BR112014005653A2 - uso de 4-amino-5-fluoro-3[6-(4-metilpiperazin-1-il)-1h-benzimidazol-2-1l]1h-quinolin-ona no tratamento de câncer de em pacientes com insuficiência hepática moderada - Google Patents

uso de 4-amino-5-fluoro-3[6-(4-metilpiperazin-1-il)-1h-benzimidazol-2-1l]1h-quinolin-ona no tratamento de câncer de em pacientes com insuficiência hepática moderada

Info

Publication number
BR112014005653A2
BR112014005653A2 BR112014005653A BR112014005653A BR112014005653A2 BR 112014005653 A2 BR112014005653 A2 BR 112014005653A2 BR 112014005653 A BR112014005653 A BR 112014005653A BR 112014005653 A BR112014005653 A BR 112014005653A BR 112014005653 A2 BR112014005653 A2 BR 112014005653A2
Authority
BR
Brazil
Prior art keywords
benzimidazol
methylpiperazin
fluoro
amino
quinolin
Prior art date
Application number
BR112014005653A
Other languages
English (en)
Portuguese (pt)
Inventor
Wynnette Reddick Catherine
Youchin Tan Eugene
Reinhard Stegert Mario
Ellen Steed Mary
Shi Michael
Prakash Anand Suraj
Wang Yongyu
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BR112014005653A2 publication Critical patent/BR112014005653A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BR112014005653A 2011-09-15 2012-09-07 uso de 4-amino-5-fluoro-3[6-(4-metilpiperazin-1-il)-1h-benzimidazol-2-1l]1h-quinolin-ona no tratamento de câncer de em pacientes com insuficiência hepática moderada BR112014005653A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161535142P 2011-09-15 2011-09-15
PCT/US2012/054046 WO2013039764A1 (en) 2011-09-15 2012-09-07 Use of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinolin-2-one in the treatment of cancer in moderate hepatic impaired patients

Publications (1)

Publication Number Publication Date
BR112014005653A2 true BR112014005653A2 (pt) 2017-03-28

Family

ID=46846036

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014005653A BR112014005653A2 (pt) 2011-09-15 2012-09-07 uso de 4-amino-5-fluoro-3[6-(4-metilpiperazin-1-il)-1h-benzimidazol-2-1l]1h-quinolin-ona no tratamento de câncer de em pacientes com insuficiência hepática moderada

Country Status (12)

Country Link
US (1) US20140221389A1 (cg-RX-API-DMAC7.html)
EP (1) EP2755655A1 (cg-RX-API-DMAC7.html)
JP (1) JP2014526506A (cg-RX-API-DMAC7.html)
KR (1) KR20140062485A (cg-RX-API-DMAC7.html)
CN (1) CN103826634A (cg-RX-API-DMAC7.html)
AU (1) AU2012308993A1 (cg-RX-API-DMAC7.html)
BR (1) BR112014005653A2 (cg-RX-API-DMAC7.html)
CA (1) CA2848210A1 (cg-RX-API-DMAC7.html)
IN (1) IN2014DN02060A (cg-RX-API-DMAC7.html)
MX (1) MX2014003182A (cg-RX-API-DMAC7.html)
RU (1) RU2014114827A (cg-RX-API-DMAC7.html)
WO (1) WO2013039764A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2764866A1 (en) 2013-02-07 2014-08-13 IP Gesellschaft für Management mbH Inhibitors of nedd8-activating enzyme
EP3093014A1 (en) * 2015-05-13 2016-11-16 Aventis Pharma S.A. Cabazitaxel and its use for treating cancer
AU2020345791A1 (en) * 2019-09-11 2022-03-31 Inspirna, Inc. Methods of treating cancer
JP7689964B2 (ja) 2019-12-13 2025-06-09 インスピルナ,インコーポレーテッド 金属塩及びその使用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0113757B8 (pt) 2000-09-11 2017-11-07 Chiron Corp derivados de quinolinona como inibidores de tirosina quinase
EP2573079A3 (en) 2002-08-23 2015-03-11 Novartis AG Benzimidazole quinolinones and uses thereof
SG148864A1 (en) * 2002-11-13 2009-01-29 Chiron Corp Methods of treating cancer and related methods
CN100377709C (zh) * 2002-11-13 2008-04-02 希龙公司 受体酪氨酸激酶抑制剂的制药用途及相关检测方法
RU2365373C2 (ru) * 2003-05-27 2009-08-27 Роберт Пер Хэгерквист Применение ингибитора тирозинкиназы для лечения диабета
EP2270000B1 (en) 2005-05-23 2015-07-29 Novartis AG Crystalline and other forms of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]-1H-quinolin-2-one lactic acid salts
AR070924A1 (es) 2008-03-19 2010-05-12 Novartis Ag Formas cristalinas y dos formas solvatadas de sales del acido lactico de 4- amino -5- fluoro-3-(5-(4-metilpiperazin-1-il ) -1h- bencimidazol-2-il) quinolin -2-(1h) - ona
BR112012012210B8 (pt) * 2009-11-23 2021-05-25 Cerulean Pharma Inc conjugado de (cdp)-taxano de polímero contendo ciclodextrina, composição, composição farmacêutica, forma de dosagem, kit e uso de um conjugado de cdp-taxano

Also Published As

Publication number Publication date
JP2014526506A (ja) 2014-10-06
WO2013039764A1 (en) 2013-03-21
EP2755655A1 (en) 2014-07-23
CA2848210A1 (en) 2013-03-21
RU2014114827A (ru) 2015-10-20
IN2014DN02060A (cg-RX-API-DMAC7.html) 2015-05-15
CN103826634A (zh) 2014-05-28
US20140221389A1 (en) 2014-08-07
AU2012308993A1 (en) 2014-03-27
KR20140062485A (ko) 2014-05-23
MX2014003182A (es) 2014-09-22

Similar Documents

Publication Publication Date Title
BR112013029246A2 (pt) 4-amino-5-flúor-3-[6- (4-metilpiperazin- 1 - il) - 1h - benzimidazol - 2 - il] - 1h - quinolin-2-ona para uso no tratamento de carcinoma adenoide cístico
BR112015029491A2 (pt) derivados de imidazopirrolidinona e seu uso no tratamento de doença
BR112014014783A2 (pt) moléculas de inibidor de jnk para tratamento de várias doenças
BR112015027282A2 (pt) fenfluramina para uso no tratamento de síndrome de dravet
BR112015029512A2 (pt) derivados de pirazolopirrolidina e seu uso no tratamento de doenças
BR112013007681A2 (pt) uso terapêutico de um agonista trl e terapia de combinação
BR112015008447A2 (pt) métodos para tratar câncer
BR112015029401A8 (pt) derivados de pirazolo-pirrolidin-4-ona, seus usos, e composição e combinação farmacêuticas
BR112015009168A2 (pt) composto de fórmula estrutural xi, uso de um composto, composição farmacêutica, método de tratamento de uma doença mediada pela pde4 em um sujeito, método de modulação de uma função mediada pela pde4 em um sujeito, método de alcançar um efeito em um paciente e método para inibir a pde4
UA114726C2 (uk) 1,4-дизаміщені аналоги піридазину та способи лікування пов'язаних з дефіцитом smn станів
BR112015014458A2 (pt) derivados de manose para o tratamento de infecções bacterianas
BR112016012410A2 (pt) conjugado de droga e anticorpo, composto conjugado de droga e anticorpo, composto não-peptídico, método de tratamento de doenças em seres humanos e composição farmacêutica
WO2015054619A3 (en) Use of a pcsk9 inhibitor to treat hyperlipidemia
IN2015DN03219A (cg-RX-API-DMAC7.html)
BRPI0507966A (pt) uso de meloxicam para o tratamento de doenças respiratórias em porcos
BR112016027041A8 (pt) combinações farmacêuticas para tratamento do câncer
BR112022003719A2 (pt) Métodos para o tratamento de hiperfenilalaninemia
BR112014001170A2 (pt) cateter, especialmente um cateter permanente, para tratamento de problemas funcionais e/ou doenças da bexiga e/ou próstata
BR112015030623A2 (pt) agentes citotóxicos para o tratamento de câncer
BR112015003836A2 (pt) sistemas e métodos para distribuição de drogas para tratamento de câncer de bexiga
BR112016027043A8 (pt) combinação, composição farmacêutica compreendendo glucocorticoide e edo-s101, kit e uso no tratamento de câncer
BR112013007343A2 (pt) métodos para tratar eritema associado com rosácea e para tratar telangiectasia associada com rosácea, e, composição tópica
ATE543492T1 (de) Behandlung von lungenkrebs
BR112015022982A2 (pt) inibidores macrocíclicos de rip2 quinase
BR112012031634A2 (pt) composto, composição farmacêutica, uso de um composto, e método para tratar um paciente que sofre de ou susceptível a um distúrbio

Legal Events

Date Code Title Description
B08F Application fees: dismissal - article 86 of industrial property law

Free format text: REFERENTE A 5A ANUIDADE.

B08K Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87)